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ABSTRACT
The cellular response to DNA damage is essential
for maintaining the integrity of the genome. Recent
evidence has identified E2F7 as a key player in DNA
damage-dependent transcriptional regulation of cell-
cycle genes. However, the contribution of E2F7 to
cellular responses upon genotoxic damage is still
poorly defined. Here we show that E2F7 represses
the expression of genes involved in the maintenance
of genomic stability, both throughout the cell cy-
cle and upon induction of DNA lesions that inter-
fere with replication fork progression. Knockdown
of E2F7 leads to a reduction in 53BP1 and FANCD2
foci and to fewer chromosomal aberrations follow-
ing treatment with agents that cause interstrand
crosslink (ICL) lesions but not upon ionizing radi-
ation. Accordingly, E2F7-depleted cells exhibit en-
hanced cell-cycle re-entry and clonogenic survival
after exposure to ICL-inducing agents. We further re-
port that expression and functional activity of E2F7
are p53-independent in this context. Using a cell-
based assay, we show that E2F7 restricts homolo-
gous recombination through the transcriptional re-
pression of RAD51. Finally, we present evidence that
downregulation of E2F7 confers an increased resis-
tance to chemotherapy in recombination-deficient
cells. Taken together, our results reveal an E2F7-
dependent transcriptional program that contributes
to the regulation of DNA repair and genomic integrity.
INTRODUCTION
Mammalian E2F transcription factors (E2F1-E2F8) are
key components of the Retinoblastoma (RB) pathway that
control cell-cycle progression through the activation or re-
pression of target genes. Deregulation of E2F activity has
a high impact on health and disease (1). An insight into
the specific functions of E2F family members has been pro-
vided by the identification of a large set of genes regulated
by each individual factor (2). These studies have revealed a
key role for RB-dependent classical E2Fs (E2F1-5) in cell-
cycle control and DNA damage response (DDR). By con-
trast, the contribution of RB-independent atypical E2F fac-
tors, E2F7-8, to these processes has not been clearly defined.
E2F7, a predominantly transcriptional repressor, is
known to be induced in late G1 by E2F1, together with a
large array of E2F target genes (3,4). E2F7 binds to promot-
ers of microRNA and protein-coding genes bearing E2F
consensus motifs, such as E2F1, CDC6, MCM2 or miR-
25 during S-phase, thereby repressing their expression (4,5).
These findings have raised the possibility that E2F7 protein
may be a key component of a negative feedback loop re-
quired to turn off transcription of E2F-driven G1/S tar-
get genes, thus allowing progression through the cell cy-
cle. Accordingly, overexpression of E2F7 blocks S-phase en-
try (4,6,7), whereas acute loss of E2F7 accelerates cell-cycle
progression (5).
Involvement of E2F7 in stress responses is supported
by various lines of evidence, although the mechanisms by
which E2F7 participates in these processes remain unre-
solved. E2F7 and E2F8 double knockout mouse embryos
exhibit widespread apoptosis, suggesting a role for these
E2Fs in cell survival (8). Furthermore, depletion of atypi-
cal E2Fs has been shown to reduce survival of tumor cells,
primary mouse keratinocytes and embryonic fibroblasts af-
ter treatment with several DNA damaging compounds, in-
dicating that sensitivity to cytotoxic/genotoxic stimuli is en-
hanced by loss of E2F7 or by the combined loss of E2F7/8
(8–10). Co-depletion of E2F1 under these circumstances
could rescue stress-induced apoptosis (8,11) and acceler-
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ate tumorigenesis in a two-stage skin carcinogenesis model
(10), implying a key role for E2F1 in E2F7/8-dependent
stress responses. Additional mediators of E2F7-dependent
resistance to DNA damaging drugs include the sphingo-
sine kinase SPHK1 and its downstream target AKT (12),
although the precise role of E2F7 in this pathway remains
to be elucidated.
Both transcription-independent and transcription-
dependent roles of E2F7 in the response to DNA damage
have been suggested. On the one hand, a recruitment of
E2F7 to the sites of DNA breaks has been reported, and
it has been suggested that E2F7 represses DNA repair
process directly on the lesion (13). On the other hand, a
p53-dependent E2F7 transactivation has been described
after treatment with DNA topoisomerase inhibitors,
which leads to repression of a subset of cell-cycle genes,
including DHFR, RRM2 and E2F1 (14), suggesting a key
transcriptional role for E2F7 in cell-cycle arrest upon DNA
damage.
Genes involved in DNA repair have been reported as tar-
gets of E2F factors, including E2F7 (4,15), but whether
E2F7 modulates responses to DNA damage through reg-
ulation of DNA repair gene expression remains to be estab-
lished. In this work we have investigated the role of E2F7
in the transcriptional regulation of genes involved in DNA
repair, and the functional consequences of E2F7-mediated
transcriptional program upon genotoxic damage. Our re-
sults suggest that E2F7 plays a p53-independent role in
the attenuation of DNA repair function through transcrip-
tional repression of target genes that are required for the
timely regulation of replication fork-associated DNA dam-
age repair.
MATERIALS AND METHODS
Cell culture and flow cytometry
Human cell lines were maintained in Dulbecco’s modified
Eagle’smedium supplementedwith fetal bovine serum (10%
for U2OS andHeLa cells; 20% for CAPAN-1 cells). For cell
synchronization inG1/S, exponentially growingU2OS cells
were incubated with 4 mM hydroxyurea (HU) for 24 h and
subsequently washed and cultured in complete medium.
For cell synchronization at mitosis, cell cultures were in-
cubated with nocodazole (50–100 ng/ml) for the last 14 h
of culture. To assess cell-cycle distribution, cells were fixed
with chilled 70% ethanol, stained with 50 g/ml propid-
ium iodide (PI) and analyzed by flow cytometry (FACSCal-
ibur, BD). To analyze the percentage ofmitotic or  -H2AX-
positive cells, ethanol-fixed cells were stained with an anti-
body recognizing Histone H3 phosphorylated on Serine 10
(pH3) conjugated with FITC (06-570, Millipore), or an an-
tibody recognizing  -H2AX protein conjugated with FITC
(05-636,Millipore), subsequently incubatedwith PI and an-
alyzed by flow cytometry. Cell-cycle distribution, mitotic in-
dex and  -H2AX accumulation analyses were performed
with Summit 4.3 software. To analyze the percentage of cells
replicatingDNA, cells were pulse-labeled with 10MBrdU
for the last 2 h of cell culture, washed in ice-cold phosphate-
buffered saline and fixed in ice-cold 70% ethanol. Cells were
stained with an antibody recognizing BrdU (M0744, Dako)
and analyzed by flow cytometry as described (16).
Generation of U2OS E2F7 knockout cells
E2F7 knockout cells were generated using the
CRISPR/Cas9 system. A CRISPR guide RNA (gRNA)
targeting the first coding exon of E2F7 was designed
using Benchling, and cloned into the BbsI site of pX330
(42230, Addgene). U2OS cells were co-transfected with this
plasmid, together with a plasmid containing a gRNA to the
zebrafish TIA gene (5′-GGTATGTCGGGAACCTCTCC-
3′) and a P2A-puromycin resistance cassette flanked by two
TIA target sites. Co-transfection results in excision of the
cassette and subsequent sporadic incorporation at the site
of the targeted genomic locus as previously described (17).
Successful integration of the cassette into the targeted gene
disrupts the allele and renders cells resistant to puromycin.
After puromycin selection, resistant clones were expanded,
screened for cassette integration and indels into the target
gene.
Clonogenic survival assays
Cells were treated with cisplatin (CSP) at the indicated con-
centrations for 24 h. Cells were then washed free of the drug
and incubated in freshmedium for 14 days or left untreated.
The number of colonies of more than 50 cells in each dish
was counted after staining with crystal violet.
Analysis of chromosomal aberrations
Chromosomal aberrations were visualized in chromosome
spreads following published protocols, with minor modifi-
cations (18). Cells were arrested in metaphase after treating
cell cultures with Karyomax Colcemid (Life Technologies)
for 12 h at a final concentration of 100 ng/ml. Metaphase-
arrested cells were subsequently harvested and fixed in
Carnoy solution. An aliquot of the cellular suspension was
dropped onto microscopy slides to obtain chromosome
spreads, which were stained and mounted with ProLong
Gold Antifade with DAPI reagent (Life Technologies). Im-
age acquisition was performed on a Leica DMI 6000B flu-
orescence microscope.
Transfections and homologous recombination assay
To silence endogenous expression of E2F7, p53, BRCA2
and RAD51, cells were transfected with commercial siR-
NAs (Life Technologies), at a final concentration of 10
nM (sequences provided in Supplementary Table S1) using
Lipofectamine RNAiMAX (Life Technologies) following
manufacturer’s recommendation. Plasmid transfection was
performed with various amounts of DNA in 6-well culture
dishes using XtremeGENEHP transfection reagent (Roche
Pharma), following manufacturer’s recommendations. The
mixture was incubated for 15 min at room temperature and
added dropwise to cell cultures.
Homologous recombination (HR)-dependentDNAdou-
ble stranded break (DSB) repair was assessed using the
DR-GFP/SceI assay described by M. Jasin’s group (19).
For these experiments we used a U2OS cell line that car-
ries a recombination substrate, DR–GFP, inserted in the
genome (U2OS DR-GFP cell line). To induce a double-
strand break in the HR reporter, U2OS-DR-GFP cells were
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transfected with I-SceI restriction enzyme expression con-
struct (pCBAI-SceI) (20). HR repair was analyzed using
flow cytometry by scoring GFP-positive cells.
RNA expression analyses
Total RNA extraction was performed with TRIzol Reagent
(Life Technologies) and purified using the RNeasy Mini kit
(Qiagen) following the manufacturer’s recommendations.
mRNAwas used to build a cDNA library using the reagents
provided in the Illumina TruSeq RNA Sample Preparation
Kit following the manufacturer’s instructions. The result-
ing purified cDNA library was sequenced on the Genome
Analyzer IIx with SBS TruSeq v5 reagents following manu-
facturer’s protocols.
Sequencing reads obtained in each condition were
mapped to the human reference genome (GRCh37/hg19)
with TopHat software tool (21). After running TopHat, the
resulting alignment files were supplied to Cufflinks tool to
generate a transcriptome assembly for each sample. The
readswere subsequently fed toCuffdiff, which calculates the
expression levels of each identified transcript and tests the
statistical significance of the expression changes between
conditions. This tool assumes that the number of sequenc-
ing reads generated from a transcript is directly propor-
tional to the relative abundance of that transcript in the
sample. Expression levels were represented by FPKM val-
ues (fragments per kilobase per million sequenced reads),
which incorporate two normalization steps to ensure that
expression levels of different transcripts can be compared
across different runs (longer transcripts produce more se-
quencing fragments than shorter transcripts and different
sequencing runs may produce different volumes of sequenc-
ing reads). Changes in gene expression between samples
were considered significant at a false discovery rate (FDR)-
adjusted P-value (q-value) < 0.05.
For individual mRNA expression analysis, RNA was
reverse-transcribed into cDNA with the High-Capacity
cDNA RT Kit (Life Technologies) and qPCR was per-
formed as described previously (22), following Minimal In-
formation for Publication of Quantitative Real-Time PCR
Experiments (MIQE) guidelines. Sequences of RT-qPCR
primers are listed in Supplementary Table S2.
Bioinformatic tools
For gene set enrichment analysis (GSEA) analyses we tested
whether 137 pathways obtained from the Pathway Inter-
action Database (NCI-Nature) are enriched among E2F7-
regulated genes. We considered as statistically enriched
those pathways with normalized enrichment scores (NES)
higher than 1.5 and FDRs < 10%.
Search for E2F motifs in E2F7-regulated genes was
carried out with the MotifLocator tool from TOUCAN
program (https://gbiomed.kuleuven.be/english/research/
50000622/lcb /tools/toucan) (23). The search was restricted
to the proximal promoter region (−1000 and +500 bp
relative to the transcription start site). Cutoffs of 0.8, 0.85
and 0.9 were applied, and the ‘Human 1 Kb Proximal 1000
ENSMUSG’ was used as background.
Identification of over-represented transcription factor
binding motifs in the regulatory regions of E2F7-regulated
genes was performed using the DiRE server (http://DiRE.
dcode.org/) (24). For these analyses, the list of up-regulated
genes and the list of downregulated genes obtained in the
RNA-seq experiments were submitted independently. A list
of 5000 human genes randomly selected byDiREwere used
as background.
Protein expression and chromatin immunoprecipitation anal-
yses
For western blot analyses, cells were lysed in buffer con-
taining 10 mM NaH2PO4 pH 7.2; 1 mM ethylenedi-
aminetetraacetic acid; 1 mM Ethylene glycol tetraacetic
acid (EGTA); 150 mM NaCl; 1% NP-40, and a cocktail of
protease and phosphatase inhibitors (Roche). Protein con-
centrations in supernatants were determined using a com-
mercially available kit (DC Protein Assay from Bio-Rad). A
total of 20 g of protein were loaded per lane, fractionated
in 8–10% sodium dodecyl sulphate-polyacrylamide gels and
transferred onto nitrocellulose membranes (Bio-Rad). An-
tibodies against the following proteins were used: E2F7
(sc-32574, Santa Cruz), Cyclin E1 (4129, Cell Signaling),
p53 (sc-1312, Santa Cruz), RAD51 (sc-8349, Santa Cruz),
pH3 (06-570, Millipore), -Tubulin (T-9026, Sigma), -
Actin (A5441, Sigma). Immunocomplexes were visualized
with horseradish peroxidase-conjugated anti-mouse, anti-
goat or anti-rabbit IgG antibodies (Santa Cruz), followed
by chemiluminiscence detection (ECL, Amersham) with a
ChemiDoc camera (Bio-Rad).
Chromatin immunoprecipitations (ChIPs) and the quan-
tification of immunoprecipitated DNA sequences by qPCR
were performed as described previously (25). Sequences of
qPCR primers are listed in Supplementary Table S3. Anti-
bodies used for ChIP analysis were: E2F7 (sc-66870, Santa
Cruz), and SV40LT (sc-147, Santa Cruz).
Immunoflorescence/high-throughput microscopy (HTM)
For standard immunofluorescence, cells were grown on cov-
erslips in 12-well plates. For FANCD2 staining, cells were
fixed for 10 min with 3.7% paraformaldehyde in phosphate-
buffered saline (PBS) and permeabilized in PBS containing
0.5% Triton X-100. Primary antibodies against FANCD2
(sc-20022, Santa Cruz) and RAD51 (sc-8349, Santa Cruz)
were applied to the coverslips for 2 h at room temperature.
After washing twice with PBS-T, samples were incubated
with the corresponding diluted fluorescent secondary an-
tibody for 1 h. Finally, samples were stained with DAPI
andmounted on amicroscopy slide using Prolong Gold an-
tifade (Life Technologies) mounting medium. Image acqui-
sition was performed on a Leica DMI 6000B fluorescence
microscope. FANCD2 foci quantification was performed
with the Definiens Tissue Phenomics analysis software.
High-throughput microscopy (HTM) was performed
with the protocol described above, except that in this case
cells were grown in 96-well plates with flattened glass bot-
tom (mCLEAR, Greiner Bio-One) at a density of 7500 cells
per well. An antibody against 53BP1 (NB100-304, Novus)
was used. As a final step nuclei were stained with a DAPI
containing solution and the preparations were kept in PBS.
Images were automatically acquired with the Opera High
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Content Screening platform (Perkin Elmer). Data analysis
was performedwith theAcapella Imaging and analysis soft-
ware (Perkin Elmer) as described previously (26). Data were
represented with the Prism software (GraphPad Software).
Statistical analysis
Data are presented as mean ± SD. The significance of the
difference between two groups was assessed using the Stu-
dent two-tailed t-test. A P < 0.05 was considered statisti-
cally significant.
RESULTS
E2F7-regulated gene expression profiling in the cell cycle
To better define E2F7 function we analyzed global gene ex-
pression profiles during the cell cycle after acute depletion
of E2F7. To this end,U2OS cells were synchronized inG1/S
transition with HU, and subsequently transfected with siR-
NAs specific for E2F7 (siE2F7) or with non-target control
siRNAs (siNT), as previously described (5). RNA was iso-
lated at three time-points following exit from cell-cycle ar-
rest, which represent G1/S transition (0 h), S phase (3 h)
andG2/Mboundary (12 h) of the cell cycle (Supplementary
Figure S1A). Kinetics of CCNE1 protein levels confirmed
the cell-cycle phases of the selected time-points, with high
levels at 0 h (G1/S) and a stepwise reduction in the follow-
ing time-points (Supplementary Figure S1B). Furthermore,
we showed efficient E2F7 protein depletion upon siE2F7
transfection, with a concomitant increase in CCNE1 lev-
els, in line with an E2F7-dependent regulation of this gene
(Supplementary Figure S1B) (7).
RNA samples were harvested from three independent ex-
periments and subsequently pooled. PolyA+ enriched sam-
ples from siNT- and siE2F7-transfected cells were used to
build cDNA libraries that were sequenced by RNA-seq.
Close to 107 high quality reads were obtained per sample.
Changes in gene expression between siE2F7-transfected rel-
ative to siNT-transfected cells were scored as significant at
q-value < 0.05. In all three time-points under study, RNA-
seq analyses showed close to 500 genes with altered expres-
sion upon E2F7 knockdown in comparison with control
cells. The proportion of overexpressed and underexpressed
genes was similar (data not shown).
We analyzed the potential pathways regulated by E2F7
by performing GSEA. We considered as significantly en-
riched the pathways with an NES above 1.5 and an FDR
below 10%. In concordance with the role of E2F7 as tran-
scriptional repressor of RB/E2F-regulated cell-cycle genes
(4), GSEA analyses showed highest enrichment values for
E2F and RB pathways (Figure 1A) among the set of E2F7-
repressed genes. This group includedmany genes previously
described as E2F targets: CCND3, CDC6, DHFR and sev-
eralMCM-s among others.
Interestingly, pathways involved in (DDR) and repair, in-
cluding BARD1, Fanconi anemia (FA) and Ataxia telang-
iectasia and Rad3-related protein (ATR) pathways were
also over-represented among the genes repressed by E2F7
in all cell-cycle phases (Figure 1A). We confirmed E2F7-
mediated repression of genes belonging to these functional
groups by RT-qPCR analysis (Figure 1B). RNAi-mediated
depletion of E2F7 resulted in a significantly increased ex-
pression of genes involved in HR-mediated repair of dam-
aged DNA (RAD51, CTIP, BARD1) or in FA pathway
(FANCE, FANCI, BRIP1). These results suggest that, in
addition to the previously reported regulation of cell-cycle
genes, E2F7might alsomediate repression of genes involved
in DNA damage response and repair pathways.
E2F7 is recruited to the promoters of DNA damage repair
genes
A search for promoter regulatory elements of the differen-
tially expressed genes showed that about 40% of overex-
pressed genes in E2F7-depleted cells harbor E2F binding
sites. In fact, the canonical E2F-binding motif was the most
over-represented transcription factor-binding site among
the upregulated set of genes in the three time-points ana-
lyzed according to DiRE analysis. By contrast, this motif
was not over-represented among the set of genes displaying
decreased mRNA levels in cells lacking E2F7. This find-
ing supports a role for E2F7 in transcriptional repression
through binding to consensus E2F motifs, in agreement
with previous data (4,5).
To identify the E2F motifs within E2F7-repressed RNAs
we made use of MotifLocator tool provided by TOUCAN
program. We focused our search on the genes belonging to
BARD1, FA and ATR pathways that showed aberrant ex-
pression upon E2F7 attenuation in at least two of the an-
alyzed time-points. Taking into account previous evidence
suggesting that E2F factors are predominantly recruited to
the proximal promoter of their target genes (4,15,27,28), we
limited our search to a region spanning −1000 to +500 bp
relative to transcription initiation. Using a threshold level
of 0.8 for similarity with the canonical E2F motif recorded
in the JASPAR database, we found that all E2F7-repressed
genes included in the selected subset harbored at least one
canonical E2F motif (Figure 2A and Supplementary Table
S4).
We next assessed E2F7 binding activity to the promot-
ers of E2F7-regulated genes by performing ChIP analyses
with an anti-E2F7 specific antibody followed by qPCR us-
ing promoter-specific primers. Amplification of the -actin
promoterwas used as a negative control, since this promoter
lacks E2F binding sites but is highly expressed inU2OS cells
(5). In addition, as a control for antibody specificity, we used
an irrelevant antibody (anti-SV40LT), which has no affinity
for chromatin and is unable to immunoprecipitate any of the
various E2F target sequences (25). As shown in Figure 2B,
ChIP analyses revealed efficient binding of E2F7 to all an-
alyzed promoters, suggesting an important role for E2F7 in
the direct transcriptional repression of DNA repair genes.
E2F7 controls cellular responses after genotoxic damage
Given the enrichment in DDR and DNA repair genes
within the list of E2F7-regulated transcripts, and having
validated several of them as direct E2F7 target genes, we
hypothesized that E2F7 could control cellular responses
following DNA damage. To test this possibility, G1/S-
synchronized cells were transfected with siNT or siE2F7,
and subsequently cultured under several genotoxic con-
ditions (Figure 3A): mitomycin C (MMC) and CSP are
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Figure 1. E2F7 represses the expression of genes involved in cell cycle and DNA repair pathways. (A) Functional classification of E2F7-regulated genes
by GSEA analysis using Pathway Interaction Database. The heat map shows the enriched pathways among the list of genes differentially expressed in cells
lacking E2F7. Normalized enrichment ratios obtained in GSEA analyses are represented as colors (red for upregulated genes, green for downregulated
genes). Only pathways with FDR< 10%were considered significantly enriched. (B) Validation of RNA-seq results. U2OS cells transfected with NT control
or E2F7 siRNAs were synchronized in the cell cycle by HU treatment. RT-qPCR analyses of indicated genes were carried out with RNA samples harvested
at 0h (G1/S), 3 h (S phase) and 12 h (G2/M) after HU treatment release. Expression values are normalized to the expression of EIF2C2, used as standard
control. Data are represented as fold-change (mean ± SEM) relative to siNT-transfected samples from three independent experiments (*, P < 0.05).
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(B) ChIP-qPCR analyses of E2F7-regulated genes. Cell lysates were harvested 3 h after HU release and used for ChIP assays with an antibody against
E2F7. Promoter regions near E2F consensus sites were amplified by qPCR. The promoter of -Actin (ACTB)was used as a negative control. An unrelated
antibody against the SV40 large T antigen (SV40LT) was used as a control for background immunoprecipitation. Data are presented as percentage of input
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CSP. For each cell line tested, cell viability of untreated cells was defined as 1. Data represent mean ± SD from two independent experiments. Ø, untreated.
known to generate DNA interstrand crosslinks (ICL), in
which FA repair pathway is involved (29), whereas  -
irradiation (IR) or neocarzinostatin (NCS), which mimics
DNA damage caused by  -IR (30) are known to induce
DNA double-stranded breaks (31).
Cell-cycle progression was assessed by recording the ac-
cumulation of pH3-positive mitotic cells after nocodazole
addition. Only a small fraction of siNT-transfected cells ex-
posed to non-lethal doses of DNA-damaging agents was
able to enter mitosis, reflecting the efficient arrest in G2
caused by these genotoxic agents (Figure 3A and Supple-
mentary Figure S2A). Strikingly, knockdown of E2F7 led
to a significant increase in the fraction of cells capable of
exiting from the G2 arrest imposed by MMC and CSP rel-
ative to siNT-transfected cells (Figure 3A). This difference
in recovery capacity between siNT and siE2F7-transfected
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cells was not observed upon ionizing radiation-induced G2
arrest. Results compiled from multiple biological replicates
of synchronized as well as asynchronous cells confirmed the
significant increase in the percentage of E2F7-silenced mi-
totic cells after treatment with MMC and CSP (Figure 3A
and Supplementary Figure S2B). Similar results were ob-
tained after treatment with Olaparib (OLA), an inhibitor
of poly(ADP-ribose) polymerase-1 (PARP1) that induces
single-strand break accumulation and reduced fork stabil-
ity (32) (Supplementary Figure S2B and C).
Given the known effect of these drugs in replication fork
progression, we next examined DNA replication rates after
knockdown of E2F7 by measuring BrdU incorporation in
asynchronously growing cells treated with CSP for 12 h. As
expected, DNA synthesis rate was reduced in siNT cells un-
der this treatment. By contrast, the reduction in DNA repli-
cation was alleviated in siE2F7 cells (Figure 3B), suggesting
that E2F7 inhibits DNA replication whenDNA lesions that
interfere with fork progression are generated.
To confirm the functional significance of E2F7 in DNA
damage responses, a CRISPR/Cas9 mediated E2F7 gene
knockout was established in U2OS cells using a gRNA
that targets the N-terminal region of E2F7 protein. Effi-
cient E2F7 knockout of a selected cell line was demon-
strated by DNA sequencing and Western analysis (Sup-
plementary Figure S3). E2F7 knockout cells were treated
with DNA damaging compounds, and pH3-positive mi-
totic cells were scored. Similarly to our finding with E2F7-
knockdown cells, the fraction E2F7 knockout cells that
was positive for pH3 was significantly increased relative to
parental E2F7 wild-type cells after ICL induction or PARP
inhibition (Figure 3C).
We next determined whether the improved cell-cycle pro-
gression of E2F7-deficient cells after genotoxic damage im-
pacted their long-term clonogenic survival. To this end, we
treated E2F7-knockout cells with CSP for 24 h and cultured
them for two additional weeks to allow for colony formation
from individual surviving cells. As shown in Figure 3D, the
number of colonies that were scored in E2F7-knockout cul-
tures exposed to CSP was significantly higher than in wild-
type cultures, in concordance with cell-cycle analyses (Sup-
plementary Figure S4). Altogether, our results suggest that
lack of E2F7 confers an increased checkpoint recovery com-
petence upon treatment with compounds that affect replica-
tion fork progression (CSP, MMC, OLA).
E2F7 expression and activity in cells exposed to DNA
crosslinkers is p53-independent
It has been reported that E2F7 expression is induced when
DNA lesions are generated upon treatment with selected
drugs (11,14).We tested whether E2F7 expression and tran-
scriptional activity are also regulated upon ICL induc-
tion. Asynchronously growing U2OS cells transfected with
siE2F7 or siNT were treated with CSP or left untreated for
24 h, and gene expression was analyzed at the mRNA level.
A significant increase in E2F7 levels was detected uponCSP
exposure, which was blocked in siE2F7-transfected cells
(Figure 4A). In contrast to E2F7 expression, the mRNA
levels of target genes involved in DNA replication and re-
pair identified in our RNA-seq were consistently reduced
upon CSP treatment. Importantly, silencing of E2F7 led
to a robust overexpression of target genes in CSP treated
cells (Figure 4A and Supplementary Figure S5). Similar re-
sults were obtained afterMMC treatment (data not shown).
These findings point to a role for E2F7 in the negative regu-
lation of genes involved in DNA damage responses during
cell-cycle progression, but also following ICL induction.
ICL damage and PARP inhibition also led to a substan-
tial induction of E2F7 at the protein level, concomitant with
p53 accumulation (Figure 4B). To determine whether the
observed accumulation of E2F7 levels wasmediated by p53,
as had been reported previously for cells treated with DNA
topoisomerase II inhibitors (14), we silenced p53 expression
by specific siRNA transfection and examined E2F7 expres-
sion upon genotoxic treatment. Remarkably, loss of p53 did
not reduce E2F7 levels (Figure 4B). In functional assays, we
found that depletion of p53 had no effect on the recovery of
U2OS cells exposed to CSP, MMC or OLA, whereas con-
comitant depletion of p53 and E2F7 led to a significant in-
crease in the number of mitotic cells (Figure 4C), suggesting
that E2F7’s role in cell-cycle recovery from ICL damage or
PARP inhibition is p53-independent.
To confirm these results we made use of HeLa cells, in
which p53 activity is very low due to human papillomavirus-
derived E6 protein expression in these cells (33). HeLa
cells that were transfected with siRNA molecules specific
for E2F7 and subsequently treated with genotoxic com-
pounds accumulated a significantly higher percentage of
pH3-positive mitotic cells compared to control cells trans-
fected with non-target siRNAs (Figure 4D). Furthermore,
exposure to CSP led to an induction of E2F7 mRNA levels
and to an upregulation of target gene expression in E2F7-
depleted HeLa cells (Figure 4E). These results suggest a
p53-independent role in the regulation of cellular responses
by E2F7 after DNA damage by ICLs and PARP inhibition.
Reduced number of DNA repair foci and chromosome breaks
after E2F7 silencing
We next considered the possibility that E2F7 could con-
tribute to themodulation of DNA repair pathways involved
in ICL resolution. To test this hypothesis, we examined the
accumulation of 53BP1 foci in the nuclei of damaged cells.
53BP1 has been involved in DNA damage signaling and re-
pair, and is well characterized for its ability to localize to
DNA lesions in cells exposed to genotoxic agents, includ-
ing ICL-inducing agents (34). U2OS cells were transfected
with E2F7-specific siRNAs and subsequently treated with
MMC, CSP or the radiomimetic drug NCS. Twenty-four
hours after treatments, cells were fixed and 53BP1 foci were
analyzed and quantified by immunofluorescence and high-
throughput microscopy (Figure 5A). As expected, treat-
ments with DNA damaging agents resulted in an increased
number of foci relative to untreated cells. Interestingly, de-
pletion of E2F7 caused a significant decrease in MMC or
CSP-induced 53BP1 foci, but did not alterNCS-derived foci
number. Furthermore, E2F7-null cells showed lower levels
of  -H2AX compared to E2F7-competent cells after 24 h of
genotoxic treatment, whereas the  -H2AX levels were com-
parable at earlier time points in both cell lines (Supplemen-
tary Figure S6). These data imply that E2F7 does not affect
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Figure 4. E2F7 expression and activity are regulated in a p53-independent manner after ICL induction and PARP inhibition. (A) Asynchronously growing
U2OS cells were transfected with siNT and siE2F7 and subsequently treated with 8 M CSP for 24 h. RT-qPCR analyses of indicated genes are shown.
Expression values are normalized to the expression of EIF2C2, used as standard control. Data are represented as fold-change (mean ± SEM) relative
to siNT-transfected samples from three independent experiments. (B) U2OS cells were transfected with siRNA molecules specific for p53 or with siRNA
control, and 24 h later treated with MMC (250 and 500 nM), CSP (4 and 8 M), OLA (2 and 4 M) or NCS (40 ng/ml) for an additional 24 h period.
E2F7 and p53 protein levels were analyzed by western blots using specific antibodies. (C) U2OS cells were HU-synchronized and transfected with siNT,
siE2F7 and/or sip53. Subsequently, cells were treated as in Figure 3B. The graphs represent fold-change over siNT values (mean ± SD) of E2F7- and/or
p53-depleted pH3-positive cells from three independent experiments. (D) Asynchronously growingHeLa cells were transfected and treated as in (A). Shown
are RT-qPCR analyses of indicated genes. (E) HeLa cells were treated as in Figure 3B, and the percentage of mitotic pH3-positive cells was analyzed by
flow cytometry. The graph represents fold-change of E2F7-depleted pH3-positive cells over siNT values (mean± SD) from three independent experiments.
Ø, untreated. (*, P < 0.05)
foci formation, but instead E2F7 plays a role in the negative
control of pathways involved specifically in ICL repair.
It has been shown that FANCD2 recruitment to sites of
DNA crosslinks is an essential step for ICL repair (35,36).
Thus, we analyzed FANCD2 foci by immunofluorescence,
and quantified the number of foci per nucleus in E2F7-
depleted cells exposed toMMCor CSP. As expected,MMC
and CSP treatments increased the number of FANCD2
foci/nucleus. Importantly, depletion of E2F7 caused a sig-
nificant decrease in MMC or CSP-induced FANCD2 foci
(Figure 5B).
We next assessed the accumulation of chromosomal aber-
rations, a hallmark of ICL-inducing agents (29,37), visual-
ized in metaphase spreads. Numerous control cells (siNT)
displayed radial and broken chromosomes (nearly 0.5 aber-
rations per metaphase) upon MMC exposure. Silencing of
E2F7 provided partial resistance against MMC-induced
chromosomal aberrations, with a reduced presence of radial
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Figure 5. E2F7 knockdown results in reduced foci and chromosome break number after ICL induction. (A) siNT and siE2F7 transfected U2OS cells
were treated with MMC, CSP and NCS and fixed 24 h later. Cells were stained for 53BP1 with a FITC-conjugated specific antibody. Nuclear DNA was
stained with DAPI. The number of 53BP1 foci was scored by HTM. Data are representative of three independent analyses. Horizontal lines indicate mean
vales. (B) siNT and siE2F7 transfected U2OS cells were treated with 250nM MMC or with 4 M CSP. Twenty fours hours later, samples were fixed and
stained for FANCD2. The number of FANCD2 foci was scored on fluorescencemicroscope images. Continuous horizontal lines indicate mean values. Data
are representative of three independent analyses. (C) siNT and siE2F7 transfected U2OS cells were treated with 250 nM MMC for 48 h and scored for
chromosomal aberrations by analyzingmetaphase spreads. Representative images of a radial chromosome and a chromatid break are shown. Chromosomal
aberrations are expressed as the average breaks and radial chromosomes found per metaphase (n= 50 cells) in three independent experiments. (*, P< 0.05;
***, P < 0.001), Ø, untreated, n.s. not significant.
and broken chromosomes (Figure 5C). Thus, E2F7 appears
to have a negative role in the repair of chromosomal aber-
rations resulting from MMC treatment. The reduction in
53BP1 and FANCD2 foci upon MMC treatment shown by
cells lacking E2F7 supports this hypothesis.
E2F7 modulates homology-directed DNA repair
Wenext investigated the efficiency ofHR in cells depleted of
E2F7.We used aU2OS cell line with an integrated direct re-
peat recombination reporter (DR-GFP).With this reporter,
homology-directed DNA repair is detected when a DSB in-
troduced into the chromosome by the I-SceI endonuclease
is repaired by HR to give rise to GFP-positive cells (20).
Knockdown of E2F7 resulted in a significant increase in
HR efficiency (Figure 6A). Conversely, overexpression of
E2F7 in U2OS-DR-GFP cells to levels that are comparable
to those observed after ICL induction led to a significant
reduction in HR efficiency, suggesting that E2F7 inhibits
HR-mediated repair.
To better define the mechanism underlying E2F7-
mediated modulation of DNA repair, we analyzed whether
the improved genomic stability conferred by loss of E2F7
could be attributed to increased expression of E2F7 tar-
get genes necessary for HR repair. We examined RAD51
recombinase activity, a surrogate marker of HR efficiency
and transcriptional target of E2F7 (Figures 1B and 2). In
E2F7-depleted U2OS cells, RAD51 foci were significantly
increased under both basal and ICL-inducing conditions
(Supplementary Figure S7), suggesting that HRmay be hy-
peractive upon loss of E2F7. Using the DR-GFP reporter
system, siRNA-mediated RAD51 depletion led to a reduc-
tion in HR repair, whereas E2F7 depletion resulted in in-
creased HR rates, as measured by the differences in the per-
centages of GFP-positive cells detected by flow cytometry
(Figure 6B). Western blot analysis of protein extracts de-
rived from E2F7-silenced cells showed overexpression of
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Figure 6. E2F7 suppresses HR through transcriptional repression of DNA repair genes. (A) U2OS-DR-GFP cells were transfected with siRNAs specific
for E2F7 or with a plasmid expressing E2F7 together with an SceI expression vector. GFP-positive cells were analyzed by FACS. Data are shown as a
percentage over siNT or over empty pCMV transfection. The values shown represent the mean ± SD of three independent experiments (*, P < 0.05). (B)
U2OS-DR-GFP cells were transfected with siRNAs specific for E2F7, RAD51 or with a combination of both and analyzed as in (A). Western blot analysis
confirms knockdown of E2F7 and RAD51 (arrow). Shown is a representative experiment of two independent experiments. A non-specific band in RAD51
blot is indicated with an asterisk.
RAD51 protein levels, in line with the mRNA results de-
scribed in Figure 1B. We next co-transfected E2F7-specific
siRNAs with a concentration of RAD51-specific siRNAs
that would attenuate RAD51 expression to the levels found
in E2F7 competent cells. Interestingly, the increased HR re-
pair efficiency conferred by loss of E2F7 was abrogated un-
der these conditions, and the percentage of GFP positive
cells decreased to the levels found in control cells (Figure 6B
and Supplementary Figure S8). These results suggest that
E2F7 modulates DNA repair through the transcriptional
repression of target genes that play a central role in the reso-
lution of DNA lesions requiring homology-directed repair,
such as RAD51. In the absence of E2F7 the HR pathway
could become hyperactive and potentially harmful.
Improved genomic stability in HR-deficient cells after E2F7
depletion
Given that E2F7 displays features of an HR inhibitor, we
next testedwhether downregulation of E2F7 could suppress
genomic instability in cells with an underlying genetic de-
fect in HR. We hypothesized that the increased recombi-
nation conferred by E2F7 depletion might promote DNA
repair and protect cells from genomic instability and cell
death. To test this possibility we used RNA interference
to attenuate the expression of BRCA2 in the U2OS DR-
GFP cell line. As expected, knockdown of BRCA2 abol-
ishedHR repair in this assay. Interestingly, we observed that
E2F7 co-depletion could improve HR in cells with reduced
BRCA2 activity, therefore ensuring genomic stability (Fig-
ure 7A and Supplementary Figure S9).We next made use of
CAPAN-1 pancreatic adenocarcinoma cells, which are de-
fective in HR due to a loss-of-function mutation of BRCA2
(38). Treatment of these cells with PARP1 inhibitor OLA
compromised cell viability as seen in short-term and long-
term clonogenic survival assays (Figure 7B and Supplemen-
tary Figure S10), consistent with the finding that cancer
cells deficient in HR repair through loss of BRCA2 are hy-
persensitive to PARP inhibitors (39). Importantly, down-
regulation of E2F7 expression inCAPAN-1 cells was associ-
ated with increased resistance to the PARP1 inhibitor OLA
(Figure 7B and Supplementary Figure S10). Thus, E2F7
knockdown confers an increased resistance to chemother-
apy in cells carrying defects in genes involved in HR.
DISCUSSION
In this work we have investigated the role of the atypical
E2F member E2F7 in DNA damage repair by analyzing its
contribution to the control of gene expression and to cellu-
lar responses upon exposure to genotoxic damage. We find
that in addition to controlling the timely expression of genes
necessary for G1/S transition and DNA replication in un-
perturbed conditions, E2F7 is involved in the negative reg-
ulation of genes controlling DNA repair pathways. Conse-
quently, E2F7 activity is associated with a suppression of
DNA repair reactions.
The expression of genes that are involved in various as-
pects of the DDR and DNA repair pathways is cell-cycle
regulated, showing highest expression in G1/S transition
and decreasing thereafter. Here, we show that the down-
regulation of these genes throughout the cell cycle is E2F7-
dependent. Interestingly, all upregulated genes included in
the DNA damage repair functional group harbor at least
one E2F binding site in their promoters, and althoughmany
of those have been previously identified as targets of clas-
sical E2F proteins (15,40–44), their regulation by E2F7
has only been demonstrated for some of them (4). Our
Downloaded from https://academic.oup.com/nar/article-abstract/46/9/4546/4953336
by UNIVERSIDAD DEL PAIS VASCO user
on 29 June 2018
4556 Nucleic Acids Research, 2018, Vol. 46, No. 9
A B
0
0.4
0.8
1.2
1.6
siNT siE2F7 siBRCA2 siBRCA2
+siE2F7
HR
 ef
fic
ien
cy
*
*
0
0.2
0.4
0.6
0.8
1
1.2
Ø OLA 10uM OLA 30uM
siNT siE2F7
Ce
ll v
iab
ilit
y
*
     10                   30
OLA μM
*
Figure 7. Improved genomic stability and survival upon E2F7 depletion in BRCA2-deficient cells. (A) Direct repeat recombination was measured in U2OS-
DR-GFP cells transfected with siRNAs specific for E2F7, BRCA2 or with a combination of both. E2F7 knockdown partly rescued the severe defect caused
by BRCA2 depletion. Data are represented as fold-change (mean ± SEM) relative to siNT-transfected samples from two independent experiments. (B)
Clonogenic survival assays were carried out with siE2F7 or siNT transfected CAPAN-1 cells treated with indicated doses of OLA. For each siRNA, cell
viability of untreated cells was defined as 1. Data represent mean ± SD from two independent experiments. Ø, untreated. (*, P < 0.05).
RNA-seq and ChIP experiments have extended the collec-
tion of direct E2F7 target genes involved in DNA repair
by demonstrating that E2F7 is recruited to the promoter
regions of RAD51, FANCE, FANCI, CTIP, BARD1 and
BRIP1, implying their direct transcriptional repression by
E2F7. An E2F7-dependent downregulation of replication
fork-associated DNA damage repair genes in the cell cy-
cle could help restrict DNA repair activities to the S phase,
which might otherwise give rise to unscheduled DNA re-
pair activity and genome instability.Exposure of siE2F7-
transfected cells to ICL-inducingDNAdamaging agents re-
sults in higher levels of DNA replication and mitotic cells
compared to siNT-transfected cells, consistent with a role
for E2F7 in cell-cycle arrest. Supporting this possibility, we
demonstrate that loss of E2F7 confers an increased recovery
competence upon treatment with DNA damage-inducing
doses of CSP,MMC or OLA, suggesting that E2F7 is a fac-
tor that controls cellular recovery during an ongoing DNA
damage response. In contrast to our findings, it has been re-
ported that lack of E2F7 sensitizes cells to topoisomerase
inhibitors by inducing apoptosis through a mechanism in-
volving E2F1 upregulation (10,11). Several reasons could
explain the disparity between our results and those from
previous studies. On the one hand, we have used a set of
genotoxic agents that are known to differ in their mech-
anism of DNA damage and in the elicited response from
the previously analyzed ones. On the other hand, the drug
doses used in our study were non-lethal although sufficient
to induce checkpoint arrest in G2, whereas previous studies
employed doses sufficiently high to induce apoptosis. Thus,
there could be a DNA damage threshold below which cells
lacking E2F7 could be involved in repairing the damage, but
above which these cells would activate cell death pathways.
Systematic analyses using a wide range of doses of a variety
of compounds may help resolve these differences.
E2F7 expression and cell-cycle target gene repression
have been previously linked to p53 after DNA damage
by topoisomerase inhibitors (14). Unexpectedly, we found
that E2F7 expression and E2F7-modulated cellular recov-
ery upon ICL damage is largely p53-independent. Our
results point to a fundamental difference in the DNA
damage-mediated regulation of E2F7 expression and func-
tion between DNA topoisomerase inhibitors and inter-
strand crosslink inducers. Further studies should determine
whether other p53 family members are involved in E2F7
regulation upon ICL induction or whether a distinct path-
waymediates E2F7 regulation in this context. In contrast to
DNA crosslinkers, ionizing radiation did not induce E2F7
expression in U2OS cells, which may explain why depletion
of E2F7 did not confer increased cellular recovery after ra-
diation.
Remarkably, our data show that E2F7 has additional
roles beyond inhibition of DNA replication in the presence
ofDNAdamage. In fact,DNAdamage foci are significantly
reduced uponMMC and CSP treatments in E2F7-depleted
cells. These results point to a uniquely increased DNA re-
pair competence upon treatment with ICL-inducing agents
in cells lacking E2F7, leading to an earlier release from the
chromatin of  -H2AX, 53BP1 and FANCD2. Our obser-
vation that E2F7 knockdown has a protective effect against
chromosomal aberrations induced byMMC treatment sup-
ports this hypothesis.
Interestingly, the FA pathway, which is known to be in-
volved in ICL repair (45), is highly enriched among E2F7-
repressed genes. ICL-resistant cell lines are known to have
elevated gene expression involving the FA/BRCA pathway,
including FANCF and RAD51C, which was suggested to
be causally related with enhanced removal of ICLs by the
resistant cells (46,47). We have found evidence that the ex-
pression of at least FANCE, FANCI, BRIP1 (also called
FANCJ) or RAD51 (also called FANCR) is directly reg-
ulated by E2F7, and that E2F7 depletion results in en-
hanced expression of these FA genes, particularly during
S/G2 phases or after DNA damage, two cellular contexts
exhibiting highE2F7 levels (5) (Figure 4B). By contrast, this
enhanced expression of E2F7 target genes was not observed
in asynchronously growing cells, probably because most of
these cells are inG1, a time-point where E2F7 levels are very
low (5) and therefore unable to repress target gene expres-
sion. It will be interesting to analyze whether a correlation
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can be found between ICL resistance and E2F7 levels in dif-
ferent cancer cell lines in unperturbed conditions, but also
upon exposure to ICL-inducing chemotherapy.
ICL repair is known to involve homology-directed repair
machinery and increased HR is associated with resistance
to ICL-inducing agents in human tumor cells (48,49). Our
results are consistent with a negative role for E2F7 in HR
repair activity. Indeed, using a DR-GFP assay to measure
the effect of E2F7 in HR, we found that E2F7 negatively af-
fectsHRactivity. A transcription-independent contribution
to DNA repair process for E2F7 and E2F1 has been previ-
ously reported, which involves the binding of these E2Fs
and recruitment of several factors to damaged DNA sites
(13,50–52). We cannot discard the possibility that there is a
transcription-independent contribution to E2F7-mediated
regulation of ICL lesion repair in our system, which should
be important to analyze. However, our data strongly sug-
gest that a major DNA damage response function of E2F7
is through transcription-dependent regulation of DNA re-
pair genes. Several genes involved in HR were found upreg-
ulated upon E2F7 depletion, including RAD51, CTIP and
BARD1, among others. Most importantly, the results ob-
tained in our E2F7/RAD51 co-depletion experiments sug-
gest that increasedHRactivity inE2F7 silenced cells is asso-
ciated with increased levels of RAD51 recombinase, imply-
ing a transcriptional role for E2F7 in repair of ICL lesions,
through upregulation of target genes involved in homology-
directed DNA repair. Thus, the transcriptional landscape
regulated by E2F7 could provide an additional level of re-
combination control in addition to that described for sev-
eral recombinases (53,54), whereby cells can interfere with
HR at different steps in the process.
Increasing recombination in HR-deficient cells might re-
sult in protective effects. Our results have revealed an in-
triguing link between genomic integrity of DNA repair-
deficient cells and E2F7. HR-deficient (BRCA2 mutated)
cells exhibit increased genomic instability and accumulation
of mutations that ultimately disrupt cell-cycle control path-
ways, leading to cancer. In this scenario, increased HR ac-
tivity conferred by inactivation of E2F7 might prevent ge-
nomic instability in the cells of these patients and protect
against cancer onset, as has been proposed for the depletion
of the PCNA-binding protein PARI (54). However, dysreg-
ulated hyper-recombination has also been associated with
increased genomic instability and resistance to genotoxic
therapy in some cellular contexts, such as after RAD51 up-
regulation (55). In fact, the increased survival of BRCA2-
deficient tumor cells treated with a PARP inhibitor that
we observe after knockdown of E2F7 implies that loss of
E2F7 in the context of HR deficiency confers resistance to
chemotherapy, a potentially harmful outcome for cancer
treatment.
Although further research will be needed to elucidate the
molecularmechanisms underlying E2F7-dependent control
of genomic stability, our data are consistent with an an-
tioncogenic function for E2F7 whereby E2F7 functions to
inhibit or to switch off repair pathways for specific DNA le-
sions. It has been reported that efficient ICL repair requires
negative regulation of the FA pathway. Once repair is com-
pleted, the repair factors have to be inactivated to avert in-
appropriate action and corruption of genetic information
(56). Thus, the inability to turn off or reset the FA path-
way after the repair of specific DNA damage sites may have
deleterious effects on genome integrity. In a similar manner,
E2F7 might counter-balance the transcriptional program
activated in response to ICL repair to fine-tune the cellular
response to DNA lesions and ensure response termination.
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